2023-09-28 14:46:10 +00:00
|
|
|
abstract: 'The advent of highly effective antiviral regimens will make the
|
|
|
|
|
|
|
|
|
|
eradication of hepatitis C in high-income countries such as the United
|
|
|
|
|
|
|
|
|
|
States technically feasible. But eradicating hepatitis C will require
|
|
|
|
|
|
|
|
|
|
escalating our response to the epidemic in key domains, including
|
|
|
|
|
|
|
|
|
|
surveillance and epidemiology, prevention, screening, care and
|
|
|
|
|
|
|
|
|
|
treatment, policy, research, and advocacy. Surveillance must be nimble
|
|
|
|
|
|
|
|
|
|
enough to quickly assess the magnitude of new transmission patterns as
|
|
|
|
|
|
|
|
|
|
they emerge. Basic prevention strategies - community-based outreach and
|
|
|
|
|
|
|
|
|
|
education, testing and counseling, and access to sterile injection
|
|
|
|
|
|
|
|
|
|
equipment and opioid substitution therapies - must be scaled up and
|
|
|
|
|
|
|
|
|
|
adapted to target groups in which new epidemics are emerging. All adults
|
|
|
|
|
|
|
|
|
|
should be screened for hepatitis C, but special efforts must focus on
|
|
|
|
|
|
|
|
|
|
groups with increased prevalence through community outreach and rapid
|
|
|
|
|
|
|
|
|
|
testing. Government, industry, and payers must work together to assure
|
|
|
|
|
|
|
|
|
|
full access to health services and antiviral drugs for everyone who is
|
|
|
|
|
|
|
|
|
|
infected. Access to the new regimens must not be compromised by
|
|
|
|
|
|
|
|
|
|
excessively high prices or arbitrary payer restrictions. Partnerships
|
|
|
|
|
|
|
|
|
|
must be forged between hepatitis providers and programs that serve
|
|
|
|
|
|
|
|
|
|
people who inject illicit drugs. Healthcare providers and systems,
|
|
|
|
|
|
|
|
|
|
especially primary care practitioners, need education and training in
|
|
|
|
|
|
|
|
|
|
treating hepatitis C and caring for substance-using populations.
|
|
|
|
|
|
|
|
|
|
Services must be provided to the disadvantaged and stigmatized members
|
|
|
|
|
|
|
|
|
|
of society who bear a disproportionate burden of the epidemic.
|
|
|
|
|
|
|
|
|
|
Environments must be created where people who use drugs can receive
|
|
|
|
|
|
|
|
|
|
prevention and treatment services without shame or stigma. Action is
|
|
|
|
|
|
|
|
|
|
needed to end the policy of mass incarceration of people who use drugs,
|
|
|
|
|
|
|
|
|
|
reduce the stigma associated with substance use, support the human
|
|
|
|
|
|
|
|
|
|
rights of people who use drugs, expand social safety net services for
|
|
|
|
|
|
|
|
|
|
the poor and the homeless, remove the legal barriers to hepatitis C
|
|
|
|
|
|
|
|
|
|
prevention, and build public health infrastructure to reach, engage, and
|
|
|
|
|
|
|
|
|
|
serve marginalized populations. Governments must take action to bring
|
|
|
|
|
|
|
|
|
|
about these changes. Public health agencies must work with penal
|
|
|
|
|
|
|
|
|
|
institutions to provide prevention and treatment services, including
|
|
|
|
|
|
|
|
|
|
antiviral therapy, to those in need in jails and prisons or on probation
|
|
|
|
|
|
|
|
|
|
or parole. Research is needed to guide efforts in each of these domains.
|
|
|
|
|
|
|
|
|
|
Strong and sustained political advocacy will be needed to build and
|
|
|
|
|
|
|
|
|
|
sustain support for these measures. Leadership must be provided by
|
|
|
|
|
|
|
|
|
|
physicians, scientists, and the public health community in partnership
|
|
|
|
|
|
|
|
|
|
with community advocates and people living with or at risk for hepatitis
|
|
|
|
|
|
|
|
|
|
C. Eliminating hepatitis C from the United States is possible, but will
|
|
|
|
|
|
|
|
|
|
require a sustained national commitment to reach, test, treat, cure, and
|
|
|
|
|
|
|
|
|
|
prevent every case. With strong political leadership, societal
|
|
|
|
|
|
|
|
|
|
commitment, and community support, hepatitis C can be eradicated in the
|
|
|
|
|
|
|
|
|
|
United States. If this is to happen in our lifetimes, the time for
|
|
|
|
|
|
|
|
|
|
action is now. This article forms part of a symposium in Antiviral
|
|
|
|
|
|
|
|
|
|
Research on ``Hepatitis C: next steps toward global eradication.{''''} (C)
|
|
|
|
|
|
|
|
|
|
2014 Elsevier B.V. All rights reserved.'
|
|
|
|
|
affiliation: 'Edlin, BR (Corresponding Author), Natl Dev \& Res Inst, 71 West 23rd
|
|
|
|
|
St,4th Floor, New York, NY 10010 USA.
|
|
|
|
|
|
|
|
|
|
Edlin, Brian R., Weill Cornell Med Coll, New York, NY 10065 USA.
|
|
|
|
|
|
|
|
|
|
Winkelstein, Emily R., Natl Dev \& Res Inst, New York, NY 10010 USA.'
|
|
|
|
|
author: Edlin, Brian R. and Winkelstein, Emily R.
|
|
|
|
|
author-email: 'bredlin.nyc@gmail.com
|
|
|
|
|
|
|
|
|
|
winkelstein@ndri.org'
|
|
|
|
|
author_list:
|
|
|
|
|
- family: Edlin
|
|
|
|
|
given: Brian R.
|
|
|
|
|
- family: Winkelstein
|
|
|
|
|
given: Emily R.
|
|
|
|
|
da: '2023-09-28'
|
|
|
|
|
doi: 10.1016/j.antiviral.2014.07.015
|
|
|
|
|
eissn: 1872-9096
|
|
|
|
|
files: []
|
|
|
|
|
issn: 0166-3542
|
|
|
|
|
journal: ANTIVIRAL RESEARCH
|
|
|
|
|
keywords: 'Hepatitis C; Disease eradication; Epidemiology; Prevention; Antiviral
|
|
|
|
|
|
|
|
|
|
therapy; Social determinants of health'
|
|
|
|
|
keywords-plus: 'INJECTION-DRUG USERS; NEW-YORK-CITY; HUMAN-IMMUNODEFICIENCY-VIRUS;
|
|
|
|
|
|
|
|
|
|
SYRINGE EXCHANGE PROGRAMS; HEALTH-CARE-DELIVERY; INFECTIOUS-DISEASE;
|
|
|
|
|
|
|
|
|
|
SAN-FRANCISCO; PUBLIC-HEALTH; HIV-INFECTION; CORRECTIONAL FACILITY'
|
|
|
|
|
language: English
|
|
|
|
|
month: OCT
|
|
|
|
|
number-of-cited-references: '186'
|
|
|
|
|
orcid-numbers: Edlin, Brian R/0000-0001-8172-8797
|
|
|
|
|
pages: 79-93
|
|
|
|
|
papis_id: 5ab2c1947d38f9ced15d5e8f99ba45ea
|
|
|
|
|
ref: Edlin2014canhepatitis
|
|
|
|
|
researcherid-numbers: Edlin, Brian R/F-2966-2018
|
|
|
|
|
times-cited: '35'
|
|
|
|
|
title: Can hepatitis C be eradicated in the United States?
|
2023-10-01 08:15:07 +00:00
|
|
|
type: article
|
2023-09-28 14:46:10 +00:00
|
|
|
unique-id: WOS:000343352600010
|
|
|
|
|
usage-count-last-180-days: '1'
|
|
|
|
|
usage-count-since-2013: '36'
|
|
|
|
|
volume: '110'
|
|
|
|
|
web-of-science-categories: Pharmacology \& Pharmacy; Virology
|
|
|
|
|
year: '2014'
|
